Capricor Therapeutics, Inc. (CAPR)

Market Cap	860.29M
Revenue (ttm)	23.23M
Net Income (ttm)	-34.11M
Shares Out	45.47M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	809,213
Open	18.39
Previous Close	18.46
Day's Range	18.22 - 19.39
52-Week Range	2.90 - 23.40
Beta	4.01
Analysts	Strong Buy
Price Target	39.29 (+107.66%)
Earnings Date	Nov 13, 2024

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR
• Website: https://www.capricor.com

Financial Performance

In 2023, Capricor Therapeutics's revenue was $25.18 million, an increase of 886.81% compared to the previous year's $2.55 million. Losses were -$22.29 million, -23.20% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $39.29, which is an increase of 107.66% from the latest price.

Price Target

$39.29

(107.66% upside)

Analyst Consensus: Strong Buy